Citigroup’s Achillion Pharmaceuticals ACHN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q1 | – | Sell |
-79,700
| Closed | -$481K | – | 7951 |
|
|
2019
Q4 | $481K | Buy |
79,700
+57,600
| +261% | +$333K | ﹤0.01% | 4448 |
|
|
2019
Q3 | $80K | Sell |
22,100
-16,600
| -43% | -$64K | ﹤0.01% | 5824 |
|
|
2019
Q2 | $104K | Buy |
38,700
+14,500
| +60% | +$42.8K | ﹤0.01% | 5843 |
|
|
2019
Q1 | $72K | Buy |
24,200
+19,300
| +394% | +$47.4K | ﹤0.01% | 6048 |
|
|
2018
Q4 | $8K | Sell |
4,900
-1,500
| -23% | -$4.24K | ﹤0.01% | 7251 |
|
|
2018
Q3 | $24K | Buy |
6,400
+4,600
| +256% | +$13.7K | ﹤0.01% | 7005 |
|
|
2018
Q2 | $5K | Sell |
1,800
-15,800
| -90% | -$53.8K | ﹤0.01% | 7372 |
|
|
2018
Q1 | $65K | Sell |
17,600
-23,500
| -57% | -$76.9K | ﹤0.01% | 5978 |
|
|
2017
Q4 | $118K | Buy |
41,100
+16,900
| +70% | +$61.4K | ﹤0.01% | 5499 |
|
|
2017
Q3 | $109K | Sell |
24,200
-1,300
| -5% | -$5.77K | ﹤0.01% | 5503 |
|
|
2017
Q2 | $117K | Sell |
25,500
-2,400
| -9% | -$9.65K | ﹤0.01% | 5234 |
|
|
2017
Q1 | $117K | Buy |
27,900
+9,300
| +50% | +$38.6K | ﹤0.01% | 5094 |
|
|
2016
Q4 | $77K | Buy |
18,600
+9,500
| +104% | +$50.5K | ﹤0.01% | 5924 |
|
|
2016
Q3 | $74K | Sell |
9,100
-600
| -6% | -$5.1K | ﹤0.01% | 5414 |
|
|
2016
Q2 | $76K | Buy |
9,700
+4,200
| +76% | +$36K | ﹤0.01% | 5300 |
|
|
2016
Q1 | $42K | Sell |
5,500
-8,300
| -60% | -$60.8K | ﹤0.01% | 6196 |
|
|
2015
Q4 | $149K | Sell |
13,800
-1,700
| -11% | -$15.5K | ﹤0.01% | 5021 |
|
|
2015
Q3 | $107K | Sell |
15,500
-9,100
| -37% | -$74.1K | ﹤0.01% | 4940 |
|
|
2015
Q2 | $218K | Buy |
24,600
+3,300
| +15% | +$31.2K | ﹤0.01% | 4369 |
|
|
2015
Q1 | $210K | Buy |
21,300
+17,200
| +420% | +$215K | ﹤0.01% | 4484 |
|
|
2014
Q4 | $50K | Buy |
+4,100
| New | +$50.1K | ﹤0.01% | 5699 |
|
Citigroup's ACHN Position: Q1 2020 in Review
Citigroup sold out of Achillion Pharmaceuticals (ACHN) in Q1 2020, closing a stake of 107,635 shares — an estimated $649K sold.
Citigroup first reported a position in ACHN in Q2 2013 and held it in 27 quarters. The position peaked at $2.24M in Q4 2016. 0 funds tracked by Wall St. Rank hold ACHN as of Q1 2020.
- Citigroup reported no remaining Achillion Pharmaceuticals position as of Q1 2020 after selling out during the quarter.
- Citigroup sold 107,635 Achillion Pharmaceuticals shares in Q1 2020, an estimated $649K.
- Citigroup first reported a position in Achillion Pharmaceuticals in Q2 2013 and held it in 27 quarters.
- Citigroup's Achillion Pharmaceuticals position peaked at $2.24M in Q4 2016.
- 0 funds tracked by Wall St. Rank held Achillion Pharmaceuticals as of Q1 2020.
Based on Citigroup's 13F filing for Q1 2020, filed 12 May 2020.